Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Woodruff PG, Barr RG, Bleecker E, et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med 2016;374:1811-21. DOI: 10.1056/NEJMoa1505971

Supplementary Appendix

New England Journal of Medicine 15-05971 Title: Clinical Significance of Symptoms in Smokers with Preserved Spirometry Corresponding Author: Prescott Woodruff, MD, MPH 11/21/2015

Table of Contents

SPIROMICS Investigators

We would like to acknowledge the following current and former investigators of the SPIROMICS sites and reading centers: Neil Alexis, PhD; Wayne Anderson, PhD; R Graham Barr, MD, DrPH; Basta PV, PhD, Eugene Bleecker, MD; Richard C Boucher, MD; Russell Bowler, MD, PhD; Elizabeth Carretta, MS; Stephanie Christenson, MD; Alejandro P Comellas, MD; Christopher B Cooper, MD, PhD; David Couper, PhD; Gerard Criner, MD; Ronald G Crystal, MD; Jeffrey L Curtis, MD; Claire Doerschuk, MD; Mark Dransfield, MD; Christine M. Freeman, PhD; MeiLan K Han, MD, MS; Nadia N Hansel, MD, MPH; Annette Hastie, PhD; Eric A Hoffman, PhD; Robert J Kaner, MD; Richard E. Kanner, MD; Kesimer M, PhD; Eric Kleerup, MD; Jerry Krishnan, MD, PhD; Lisa LaVange, MA, PhD; Stephen C Lazarus, MD; Fernando J Martinez, MD, MS; Deborah A Meyers, PhD; John D Newell Jr, MD; Elizabeth C Oelsner, MD, MPH; Wanda O'Neal, PhD; Robert Paine, III, MD; Nirupama Putcha, MD, MHS; Steve Rennard, MD; Donald Tashkin, MD; Mary Beth Scholand, MD; Robert A Wise, MD; and Prescott G Woodruff, MD, MPH. The project officers from the Lung Division of the National Heart, Lung, and Blood Institute (NHLBI) were Lisa Postow, PhD, and Thomas Croxton, PhD, MD.

Figure S1. Current and former smokers (ever-smokers) with preserved spirometry and symptoms (CAT≥10) had elevations in all components of the CAT score.




Figure S2. Relationship between post-bronchodilator FEV1/FVC and number of exacerbations in non-smoking healthy controls, ever-smokers with preserved spirometry and GOLD 1&2 participants stratified by symptoms (CAT<10 vs. CAT≥10). Vertical red line denotes the border between "preserved spirometry" and GOLD 1 COPD.




Figure S3. No increase in emphysema in ever-smokers with preserved spirometry and symptoms (CAT \geq 10). Percentage of lung with a density < -950 Hounsfield units on CT, a measure of emphysema. Ever-smokers with preserved spirometry do not have increased emphysema whether CAT score is \geq or < 10.




Figure S4. Airway wall thickening. Pi10 (defined as the square root of the wall area of a theoretical airway of 10 mm lumenal perimeter) is a CT measure of airway wall thickening. Ever-smokers with preserved spirometry and increased symptoms (CAT score ≥ 10) have evidence of increased airway wall thickening by CT.




Figure S5. Individual COPD Assessment Test (CAT) Component Scores in smokers with preserved spirometry, stratified by current versus former smoking. In ever-smokers with preserved spirometry and symptoms (CAT \geq 10), the elevations we observed in each component of the CAT score are independent of whether they are current or former smokers.




Figure S6. Prospective exacerbations in smokers with preserved spirometry stratified by current versus former smoking. In smokers with preserved spirometry and symptoms ($CAT \ge 10$), the elevation in exacerbation risk that we observed is independent of whether they are current or former smokers.






Figure S7. ROC analysis of the value of baseline CAT score versus post-bronchodilator FEV_1 for predicting the occurrence of any exacerbation in the first year of follow-up among current and former smokers with preserved spirometry. Participants with < 1 year of follow-up were excluded.



Any Exacerbations (AUC difference: p = 0.05)

Figure S8. ROC analysis of CAT score as compared to the Medical Research Council (MRC) score for predicting the occurrence of any exacerbation over the first year of follow-up in ever-smokers with preserved spirometry. CAT was similar to MRC score for prediction of any exacerbation. Participants with < 1 year of follow-up were excluded.



Any Exacerbations (AUC difference: p = 0.27)

	Group A Never-smoking Controls	Group B Ever-Smokers with preserved spirometry and CAT<10 (less symptoms)	Group C Ever-Smokers with preserved spirometry and CAT ≥10 (more symptoms)	Group D Ever-Smokers with GOLD 1 & 2 COPD and CAT<10 (less symptoms)	Group E Ever-Smokers with GOLD 1 & 2 COPD and CAT≥10 (more symptoms)
N	199	424	425	337	626
Six minute walk distance (meters)	479.5±101.9	461.7±91.4	410.2±96.0	452.1±100.7	399.3±118.3
	* vs. C,D,E	* vs. C,E	* vs. A,B,D	* vs. A,C,E	* vs. A,B,D
Six minute walk distance (%	89.7±18.7	89.3±18.8	79.8±19.2	89.2±19.3	79.3±24.0
predicted)	* vs. C,E	* vs. C,E	* vs. A,B,D	* vs. C,E	* vs. A,B,D
Pre-BD FEV1 (L)	2.86±0.70 L	2.73±0.69 L	2.48±0.68 L	2.01±0.68 L	1.76±0.61 L
	* vs. C,D,E	* vs. C,D,E	* vs. A,B,D,E	* vs. A,B,C,E	* vs. A,B,C,D
Pre-BD FEV1 (% predicted)	97.2±11.6%	93.5±13.6%	88.0±13.9%	68.7±16.4%	61.8±15.3%
	* vs. B,C,D,E	* vs. A,C,D,E	* vs. A,B,D,E	* vs. A,B,C,E	* vs. A,B,C,D
Post-BD FEV ₁ (L)	2.96±0.72 L	2.88±0.71 L	2.65±0.70 L	2.25±0.68 L	2.01±0.62 L
	* vs. C,D,E	* vs. C,D,E	* vs. A,B,D,E	* vs. A,B,C,E	* vs. A,B,C,D
Post-BD FEV ₁ (% predicted)	101±11.0%	98.5±12.6%	94.1±13.1%	77.1±15.2%	70.5±14.3%
	* vs. C,D,E	* vs. C,D,E	* vs. A,B,D,E	* vs. A,B,C,E	* vs. A,B,C,D
Post-BD FEV ₁ % improvement	4.1±5.9	6.1±5.5	7.4±7.9	13.7±11.6	16.2±14.5
	* vs. C,D,E	* vs. D,E	* vs. A,D,E	* vs. A,B,C,E	* vs. A,B,C,D
FEV ₁ bronchodilator responsive, (Y, %) (Pellegrino)	13 (7%)	43 (10%)	66 (15%)	146 (44%)	273 (44%)

Table S1: Between group difference in walk distance, lung function, respiratory medication use and prospective exacerbation rates.

	* vs. C,D,E	* vs. D,E	* vs. A,D,E	* vs. A,B,C	* vs. A,B,C
Pre-BD FVC (L)	3.68±0.91 L	3.73±0.91 L	3.39±0.91 L	3.57±1.01 L	3.24±0.97 L
	* vs. C,E	* vs. C,E	* vs. A,B	* vs. C	* vs. A,B,D
Pre-BD FVC (% predicted)	97.4±10.2%	97.5±12.6%	93.0±13.0%	91.7±17.3%	86.3±16.5%
	* vs. C,D,E	* vs. C,D,E	* vs. A,B,E	* vs. A,B,E	* vs. A,B,C,D
Post-BD FVC (L)	3.69±0.92 L	3.77±0.91 L	3.48±0.90 L	3.85±0.99 L	3.58±1.00 L
	no p<0.05	* vs. C,E	* vs. B,D	* vs. C,E	* vs. B,D
Post-BD FVC (% predicted)	97.8±9.9%	98.5±11.6%	95.7±12.4%	99.4±16.4%	95.2±15.9%
	no p<0.05	* vs. C,E	* vs. B,D	* vs. C,E	* vs. B,D
Post-BD FVC % improvement	0.4±4.2	1.5±4.8	3.0±7.1	9.0±9.3	11.3±11.0
	* vs. C, D,E	* vs. D,E	* vs. A,D,E	*vs. A,B,C,E	* vs. A,B,C,D
FVC BD responsive (Y, %)	3 (2%)	9 (2%)	34 (8%)	108 (32%)	225 (36%)
(Pellegrino)	* vs. C,D,E	* vs. C,D,E	* vs. A,B,D,E	* vs. A,B,C	* vs. A,B,C
Pre-BD inspiratory capacity (L)	2.76±0.74 L	2.77±0.72 L	2.53±0.73 L	2.66±0.79 L	2.45±0.75 L
	* vs. C,E	* vs. C,E	* vs. A,B	* vs. E	* vs. A,B,D
Post-BD inspiratory capacity (L)	2.84±0.76	2.89±0.75	2.71±0.74	2.88±0.84	2.67±0.81
	no p<0.05	* vs. C,E	* vs. B,D	* vs. C,E	* vs. B,D
Inhaled steroids in the past 3 mo	5 (3%)	11 (3%)	98 (23%)	74 (22%)	285 (46%)
(yes, %)	* vs. C,D,E	* vs. C,D,E	* vs. A,B,E	* vs. A,B,E	* A,B,C,D
Inhaled bronchodilators in the past 3	9 (5%)	32 (8%)	178 (42%)	129 (39%)	415 (67%)
mo (yes, %)	* vs. C,D,E	* vs. C,D,E	* vs. A,B,E	* vs. A,B,E	* vs. A,B,C,D
% Emphysema (HU <-950 on CT scan)	1.59±1.76%	1.97±2.09%	1.61±2.22%	7.10±7.36%	7.19±7.14%

	* vs. D,E	* vs. D,E	* vs. D,E	* vs. A,B,C	* vs. A,B,C
Airway wall thickness (Pi10)	3.68±0.090	3.70±0.090	3.73±0.090	3.71±0.110	3.73±0.110
	* vs. C,D,E	* vs. C,E	* vs. A,B	* vs. A,E	* vs. A,B,D
Prospective rate of exacerbations (and	nualized)			I	
Antibiotics	0.022±0.139	0.062±0.268	0.185±0.521	0.129±0.310	0.398±0.783
	* vs. C,D,E	* vs. C,D,E	* vs. A,B,E	* vs. A,B,E	* vs. A,B,C,D
Steroids	0.021±0.199	0.022±0.141	0.158±0.531	0.071±0.229	0.305±0.710
	* vs. C,D,E	* vs. C,D,E	* vs. A,B,E	* vs. A,B,E	* vs. A,B,C,D
Either antibiotics or steroids	0.032±0.209	0.069±0.295	0.226±0.608	0.144±0.349	0.457±0.844
	* vs. C,D,E	* vs. C,D,E	* vs. A,B,E	* vs. A,B,E	* vs. A,B,C,D
Health care visit (office visit, ED	0.020±0.176	0.073±0.285	0.243±0.626	0.155±0.363	0.426±0.785
or hospital)	* vs. B,C,D,E	* vs. A,C,D,E	* vs. A,B,E	* vs. A,B,E	* vs. A,B,C,D
Any exacerbation	0.032±0.209	0.076±0.311	0.266±0.674	0.175±0.380	0.496±0.868
	* vs. C,D,E	* vs. C,D, E	* vs. A,B,E	* vs. A,B,E	* vs. A,B,C,D
Severe exacerbation (ED or	0.008±0.097	0.004±0.059	0.086±0.292	0.040±0.171	0.159±0.410
hospitalization)	* vs. C,D,E	* vs. C,D,E	* vs. A,B,E	* vs. A,B,E	* vs. A,B,C,D

* denotes p<0.05 for each pairwise comparison (vs. the group indicated) by oneway ANOVA for continuous variables, chi-square for categorical variables and Kruskal-Wallis test for exacerbation rates with Bonferroni correction for multiple comparisons across the 5 groups (10 comparisons). Table S2. Physiological measures associated with CAT score ≥ 10 , while controlling for potential confounders. Includes ever-smokers with preserved spirometry who have symptoms (CAT ≥ 10) and are asymptomatic (CAT< 10, referent)

		Me	odel 1			Мо	odel 2			М	odel 3			M	odel 4	
Outcome	Beta	(95%	CI)	P-value												
6 Minute Walk Distance	-49.69	(-62.62,	-36.76)	<0.001	-41.42	(-54.47,	-28.37)	<0.001	-39.24	(-52.57,	-25.91)	<0.001	-40.90	(-54.08,	-27.73)	<0.001
6 Minute Walk, % Predicted	-9.00	(-11.61,	-6.39)	<0.001	-8.22	(-10.77,	-5.67)	<0.001	-7.70	(-10.30,	-5.11)	<0.001	-8.12	(-10.69,	-5.55)	<0.001
Pre-BD FEV1	-0.27	(-0.36,	-0.18)	<0.001	-0.17	(-0.23,	-0.10)	<0.001	-0.15	(-0.22,	-0.09)	<0.001	-0.17	(-0.23,	-0.10)	<0.001
Pre-BD FEV1, % Predicted	-5.63	(-7.53,	-3.72)	<0.001	-4.87	(-6.88,	-2.86)	<0.001	-4.44	(-6.48,	-2.41)	<0.001	-4.85	(-6.87,	-2.83)	<0.001
Pre-BD FVC	-0.36	(-0.48,	-0.23)	<0.001	-0.18	(-0.26,	-0.10)	<0.001	-0.17	(-0.25,	-0.09)	<0.001	-0.18	(-0.26,	-0.10)	<0.001
Pre-BD FVC, % Predicted	-4.52	(-6.29,	-2.75)	<0.001	-3.87	(-5.69,	-2.05)	<0.001	-3.78	(-5.63,	-1.93)	<0.001	-3.98	(-5.81,	-2.15)	<0.001
Post-BD FEV1	-0.25	(-0.34,	-0.15)	<0.001	-0.14	(-0.20,	-0.08)	<0.001	-0.13	(-0.20,	-0.07)	<0.001	-0.14	(-0.20,	-0.08)	<0.001
Post-BD FEV1, % Predicted	-4.59	(-6.35,	-2.84)	<0.001	-3.88	(-5.72,	-2.05)	<0.001	-3.73	(-5.60,	-1.86)	<0.001	-3.91	(-5.76,	-2.06)	<0.001
Post-BD FVC	-0.31	(-0.43,	-0.19)	<0.001	-0.13	(-0.21,	-0.06)	<0.001	-0.14	(-0.22,	-0.06)	<0.001	-0.14	(-0.22,	-0.06)	<0.001
Post-BD FVC, % Predicted	-3.00	(-4.64,	-1.36)	<0.001	-2.55	(-4.25,	-0.86)	0.003	-2.75	(-4.48,	-1.03)	0.002	-2.72	(-4.42,	-1.01)	0.002
Pre-BD Inspiratory Capacity	-0.25	(-0.35,	-0.15)	<0.001	-0.16	(-0.24,	-0.09)	<0.001	-0.16	(-0.24,	-0.08)	<0.001	-0.16	(-0.24,	-0.09)	<0.001
Post-BD Inspiratory Capacity	-0.19	(-0.29,	-0.09)	<0.001	-0.10	(-0.17,	-0.02)	0.01	-0.10	(-0.18,	-0.02)	0.01	-0.10	(-0.17,	-0.02)	0.01
FEV1 BD Reversibility, Percent	1.25	(0.31,	2.18)	0.009	1.07	(0.08,	2.06)	0.03	0.73	(-0.27,	1.73)	0.15	1.01	(0.02,	2.00)	0.05
FVC BD Reversibility, Percent	1.49	(0.64,	2.34)	<0.001	1.25	(0.35,	2.15)	0.006	0.95	(0.05,	1.86)	0.04	1.21	(0.30,	2.11)	0.009

Model 1 = Symptomatic group (CAT<10 vs CAT >=10).

Model 2 = Model 1 + BMI, current smoking status, age, gender, race, ethnicity.

Model 3 = Model 2 + self-reported comorbidities (congestive heart failure, GERD self-report, any asthma diagnosis).

Model 4 = Model 2 + self-reported comorbidities (congestive heart failure, GERD self-report, childhood asthma diagnosis).

Results are from linear models.

Table S3. Risk for exacerbation associated with CAT score ≥ 10 excluding participants with any diagnosis of asthma at baseline while controlling for potential confounders. Includes ever-smokers with preserved spirometry who were symptomatic (CAT ≥ 10) and asymptomatic (CAT< 10, referent)

		N	lodel 1			I	Model 2			/	Model 3	
Outcome	RR	(95%	CI)	P-value	RR	(95%	CI)	P-value	RR	(95%	CI)	P-value
Exacerbations, Any	2.23	(1.29,	3.83)	0.004	2.06	(1.19,	3.57)	0.01	1.95	(1.12,	3.42)	0.02
Exacerbations, Antibiotics	1.92	(1.07,	3.45)	0.03	1.81	(0.99,	3.28)	0.05	1.72	(0.94,	3.14)	0.08
Exacerbations, Steroids	3.93	(1.86,	8.30)	<0.001	3.96	(1.84,	8.49)	<0.001	3.89	(1.78,	8.49)	<0.001
Exacerbations, Antibiotics or Steroids	1.99	(1.12,	3.52)	0.02	1.88	(1.04,	3.41)	0.04	1.79	(0.98,	3.27)	0.06
Exacerbations, HCU	2.31	(1.37,	3.89)	0.002	2.12	(1.24,	3.61)	0.006	2.02	(1.17,	3.47)	0.01
Exacerbations, Severe	10.91	(2.82,	42.19)	<0.001	9.77	(2.30,	41.43)	0.002	9.56	(2.28,	40.11)	0.002

Model 1 = Symptomatic group (CAT<10 vs CAT >=10).

Model 2 = Model 1 + BMI, current smoking status, age, gender, race, ethnicity.

Model 3 = Model 2 + self-reported comorbidities (congestive heart failure, GERD self-report).

P-value from the Wald test for Type 3 effect.

Results are from proportional means models, modeling exacerbations as recurrent events.

Table S4. Risk for exacerbation associated with CAT score ≥ 10 excluding participants with a childhood diagnosis of asthma while controlling for potential confounders. Includes ever-smokers with preserved spirometry who were symptomatic (CAT ≥ 10) and asymptomatic (CAT<10, referent)

		N	lodel 1			N	lodel 2			N	lodel 3	
Outcome	RR	(95%	CI)	P-value	RR	(95%	CI)	P-value	RR	(95%	CI)	P-value
Exacerbations, Any	3.43	(2.01,	5.84)	<0.001	2.85	(1.65,	4.92)	<0.001	2.67	(1.56,	4.57)	<0.001
Exacerbations, Antibiotics	3.01	(1.71,	5.32)	<0.001	2.51	(1.41,	4.49)	0.002	2.37	(1.34,	4.20)	0.003
Exacerbations, Steroids	7.68	(3.55,	16.62)	<0.001	6.52	(3.00,	14.17)	<0.001	6.14	(2.86,	13.15)	<0.001
Exacerbations, Antibiotics or Steroids	3.18	(1.81,	5.59)	<0.001	2.70	(1.51,	4.83)	<0.001	2.53	(1.43,	4.48)	0.002
Exacerbations, HCU	3.37	(2.01,	5.64)	<0.001	2.77	(1.62,	4.74)	<0.001	2.59	(1.53,	4.37)	<0.001
Exacerbations, Severe	16.50	(4.34,	62.66)	<0.001	11.45	(2.88,	45.47)	<0.001	10.85	(2.74,	43.05)	<0.001

Model 1 = Symptomatic group (CAT<10 vs CAT >=10).

Model 2 = Model 1 + BMI, current smoking status, age, gender, race, ethnicity.

Model 3 = Model 2 + self-reported comorbidities (congestive heart failure, GERD self-report).

P-value from the Wald test for Type 3 effect.

Results are from proportional means models, modeling exacerbations as recurrent events.

Table S5. Sensitivity and Specificity values for baseline CAT Score and the occurrence of any exacerbations over the first year of follow-up Participants with < 1 Year of Follow-up were excluded.

CAT Score	Sensitivity	Specificity
0	1.000	0.000
1	0.971	0.034
2	0.971	0.066
3	0.957	0.112
4	0.928	0.181
5	0.928	0.232
6	0.870	0.312
7	0.870	0.378
8	0.768	0.429
9	0.754	0.487
10	0.754	0.539
11	0.710	0.584
12	0.652	0.627
13	0.623	0.657
14	0.565	0.688
15	0.565	0.719
16	0.507	0.762
17	0.478	0.790
18	0.420	0.808
19	0.406	0.825
20	0.348	0.862
21	0.333	0.879
22	0.304	0.886
23	0.290	0.899
24	0.261	0.917
25	0.217	0.932

CAT Score	Sensitivity	Specificity
26	0.203	0.949
27	0.174	0.962
28	0.130	0.966
29	0.087	0.969
30	0.029	0.974
31	0.029	0.978
32	0.014	0.982
33	0.000	0.986
34	0.000	0.988
35	0.000	0.991
37	0.000	0.995
38	0.000	0.998